Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease

Boehringer Ingelheim

Status: Completed

Conditions: Parkinson Disease

Treatments: Drug: Pramipexole

Study type: Observational

Funder types: Industry

Identifiers

NCT02248207

248.527

Details and patient eligibility

About

Study to obtain information about the co-operation of the different physician-colleagues in the treatment of patients with Parkinson's disease, both in private practices and clinics and about the primary treatment strategies in the pharmacotherapy of Parkinson's disease and to collect data on the tolerability of Sifrol® in ambulatory patients suffering from Parkinson's disease under routing conditions

Enrollment: 1,293 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Parkinson's disease who present to the specialist neurologist practice for the first time without or with referral and who are planned to receive or either be switched to Sifrol or continue the previously prescribed therapy with Sifrol® can be included in this observational study

Exclusion criteria

• Neurologists are asked to consider the Summary of Product Characteristics (SPC) for Sifrol®

Trial design

1,293 participants in 1 patient group

Parkinson Disease patients

Treatment:

Drug: Pramipexole